benmelstobart combined with chemotherapy

Phase 2Small molecule

benmelstobart combined with chemotherapy is one of 67 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung CancerActive, not recruiting

Small Cell Lung CancerActive, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Small Cell Lung CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Preclinical

31 2

Gemzar

GGynecologic Oncology Group

Preclinical

72 3

PORTRAZZA

Eli Lilly

Preclinical

8 4

Lenvima

Eisai

Preclinical

6 5

Imjudo

AstraZeneca

Preclinical

5 6

Gilotrif

Boehringer Ingelheim

Preclinical

12 7

Ofev

Boehringer Ingelheim

Preclinical

7 8

benmelstobart combined with chemotherapy

XXinqiao Hospital of Chongqing

Phase 2

1 9

Tyrosine Kinase Inhibitor

Pfizer

Preclinical

2 10

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Not yet recruiting

Small Cell Lung Cancer

NCT06978153

Phase 2Recruiting

Non-Small Cell Lung Cancer

NCT06953843

Clinical

Trials by Indication[1]

Small Cell Lung Cancer1 trial

This is a Two-cohort, Exploratory Clinical Study Assessing the Activity of Benmelstobart Combined With Chemotherapy With or Without Anlotinib in Resectable Limited-Stage Small Cell Lung Cancer

Not yet recruiting·TTang-Du Hospital·Phase 2·NCT06978153·66 enrolled

Non-Small Cell Lung Cancer1 trial

Study on the Optimal Combination Pattern of the Combined Treatment of Radiotherapy and Immunotherapy for the Abscopal Effect in Non-Small Cell Lung Cancer (NSCLC) With Multiple Metastases

Recruiting·XXinqiao Hospital of Chongqing·Phase 2·NCT06953843·366 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for benmelstobart combined with chemotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — benmelstobart combined with chemotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for benmelstobart combined with chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Xinqiao Hospital of Chongqing company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: XXinqiao Hospital of Chongqing

benmelstobart combined with chemotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Small Cell Lung Cancer1 trial

Non-Small Cell Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News